Genelux Co. (NASDAQ:GNLX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Genelux in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.16) for the quarter. HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux's Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.
Genelux (NASDAQ:GNLX - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09).
Genelux Price Performance
Shares of NASDAQ GNLX traded up $0.05 during mid-day trading on Wednesday, reaching $3.08. 203,076 shares of the company traded hands, compared to its average volume of 205,897. The stock has a fifty day simple moving average of $4.06 and a 200-day simple moving average of $3.10. The firm has a market cap of $106.38 million, a PE ratio of -3.24 and a beta of -1.41. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $6.50.
Institutional Investors Weigh In On Genelux
Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP grew its position in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after buying an additional 52,958 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Genelux during the fourth quarter worth $41,000. LPL Financial LLC lifted its holdings in shares of Genelux by 72.3% during the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company's stock valued at $222,000 after purchasing an additional 39,516 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Genelux in the 4th quarter valued at $25,000. Finally, LifeSteps Financial Inc. increased its stake in Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock worth $205,000 after purchasing an additional 8,715 shares in the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Further Reading
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
